REO 017: A Phase 2 Study of Reolysin® in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma

Study Status

Closed to Enrollment

Study Description

The purpose of this study is to determine if combining REOLYSIN® with gemcitabine, the most common chemotherapy treatment, is effective in treating advanced or metastatic pancreatic cancer.

REOLYSIN® is a new form of cancer treatment that uses a type of virus called reovirus. This virus is commonly found in natural situations throughout the world (such as ponds and ditches) and may be associated with minor breathing or stomach upsets in humans.  Infection of cancer cells by this virus can slow cancer lesion growth and kill cancerous cells. The virus can cause a common cold in people but the virus is usually passed without causing harm.

The length of time you will be involved in this study will depend on how well you tolerate therapy with this treatment combination and how your disease responds. You can continue to receive the gemcitabine/REOLYSIN® treatment if your disease has not progressed or worsened, or for as long as your study doctor and you feel that you are receiving benefit.  You will be followed one month after your last dose of the study treatment and then every three months, if possible, for as long as you are well and able to attend study visits.

Disease Status and/or Stage

Advanced or Metastatic Pancreatic Cancer

Key Eligibility

  • Advanced or metastatic pancreatic cancer
  • Have not received any prior chemotherapy or biotherapy
  • Detailed eligibility reviewed when you contact the study team

Principal Investigator

Allyson Ocean, MD


Healthy Volunteers


As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.

Contact Us

For general inquiries, or if you need assistance finding a study, please contact:

Erica Bersin
Tel: (646) 962-8232
[email protected]

Top of page